Participants 610 853 11
Eligibility included localized prostate cancer with an elevated prostate-specific antigen (PSA) < or = 100 ng/mL and an estimated risk of lymph node (LN) involvement of 15%. Between April 1, 1995, and June 1, 1999, 1,323 patients were accrued.
Participants 1641 1689 3
in patients with a risk of LN involvement of 15%
